PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells

Histone deacetylase inhibitors (HDACi) have become a promising new avenue for cancer therapy, and many are currently in Phase I/II clinical trials for various tumor types. In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rivera-Del Valle, Nilsa, Gao, Shan, Miller, Claudia P., Fulbright, Joy, Gonzales, Carolina, Sirisawad, Mint, Steggerda, Susanne, Wheler, Jennifer, Balasubramanian, Sriram, Chandra, Joya
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi Publishing Corporation 2010
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2817379/
https://ncbi.nlm.nih.gov/pubmed/20145726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2010/207420
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak